LEADER 03687nam  2200649Ia 450 
001 9910820577203321
005 20240417004315.0
010   $a0-309-17865-7
010   $a1-281-80023-6
010   $a9786611800239
010   $a0-309-10743-1
035   $a(CKB)1000000000705282
035   $a(EBL)3378407
035   $a(SSID)ssj0000097237
035   $a(PQKBManifestationID)11122248
035   $a(PQKBTitleCode)TC0000097237
035   $a(PQKBWorkID)10113248
035   $a(PQKB)11492283
035   $a(MiAaPQ)EBC3378407
035   $a(Au-PeEL)EBL3378407
035   $a(CaPaEBR)ebr10255035
035   $a(CaONFJC)MIL180023
035   $a(OCoLC)923279359
035   $a(EXLCZ)991000000000705282
100   $a20080917d2008      ua         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aAddressing the barriers to pediatric drug development $eworkshop summary /$fCori Vanchieri, Adrienne Stith Butler, and Andrea Knutsen, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Press$dc2008
215   $a1 online resource (65 p.)
300   $aDescription based upon print version of record.
311   $a0-309-10742-3 
320   $aIncludes bibliographical references (p. 41-42).
327   $a""Reviewers""; ""Contents""; ""Summary""; ""1 Introduction""; ""2 Regulatory Framework""; ""3 Current Challenges in Developing and Prescribing Drugs for Children""; ""4 Models for Enhancing Pediatric Drug Development""; ""5 Challenges and Opportunities for the Future""; ""References""; ""Appendixes""; ""Appendix A: Workshop Agenda""; ""Appendix B: Speaker Biographies""
330   $aDecades of research have demonstrated that children do not respond to medications in the same way as adults. Differences between children and adults in the overall response to medications are due to profound anatomical, physiological, and developmental differences. Although few would argue that children should receive medications that have not been adequately tested for safety and efficacy, the majority of drugs prescribed for children--50 to 75 percent-- have not been tested in pediatric populations. Without adequate data from such testing, prescribing drugs appropriately becomes challenging for clinicians treating children, from infancy through adolescence. Addressing the Barriers to Pediatric Drug Development is the summary of a workshop, held in Washington, D.C. on June 13, 2006, that was organized to identify barriers to the development and testing of drugs for pediatric populations, as well as ways in which the system can be improved to facilitate better treatments for children.
606   $aDrugs$xTesting$xLaw and legislation$zUnited States
606   $aPediatric pharmacology$xLaw and legislation$zUnited States
606   $aPediatric pharmacology$xResearch$zUnited States
615  0$aDrugs$xTesting$xLaw and legislation
615  0$aPediatric pharmacology$xLaw and legislation
615  0$aPediatric pharmacology$xResearch
676   $a615.58083
701   $aButler$b Adrienne Stith$01593881
701   $aKnutsen$b Andrea$01712474
701   $aVanchieri$b Cori$01694095
712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910820577203321
996   $aAddressing the barriers to pediatric drug development$94104648
997   $aUNINA